I have thought about this for a while. I'm not sure how this company would be taken out even after aGVHD approval given the 2 blockbuster applications (CLBP and CHF) are not resolved but are closer than ever to the finishing line. These would indications would dwarf any valuation purchased based on aGVHD. And I'm not sure any Pharma would be prepared t pay an extreme premium based on potential approval of these 2 indications. Such a premium would be a multiple of a premium of an already high premium just for aGVHD. Can't see it happening.
For SI and GG to sell out at the beginning of the actual sustainable commercialization of MSB as a biotech after this many years, makes no sense to me.
MSB Price at posting:
90.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)